DESTINY-Breast03 Phase 3 Study Results

Adverse Events of Special Interest Adjudicated as drug-related ILD/pneumonitisa n (%) Grade 1 T-DXD (n = 371) 13 (3.5) TPC (n = 172) 1 (0.6) Left ventricular dysfunction n (%) Grade 2 Grade 3 Grade 4 24 (6.5) 0 5 (1.3) 0 0 0 Daiichi-Sankyo DESTINY-Breast04 Grade 5 3 (0.8) Any Grade 45 (12.1) 0 1 (0.6) Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Any Grade Ejection fraction decreased T-DXd (n = 371) TPC (n = 172) 1 (0.3) 0 14 (3.8) 0 1 (0.3) 0 0 16 (4.3) 0 0 0 0 Cardiac failurec T-DXd (n = 371) 0 TPC (n = 172) 0 1 (0.3) 0 1 (0.3) 0 0 0 0 0 2 (0.5) 0 ILD, interstitial lung disease; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician's choice. "Median time to onset of ILD/pneumonitis for patients with T-DXd was 129.0 days (range, 26-710). "Left ventricular dysfunction was reported in a total of 17 (4.6%) patients in the T-DXd arm. One patient initially experienced ejection fraction decrease, then later developed cardiac failure. *Both patients with cardiac failure were reported to have recovered. ASCO 2022 #LBA3 Plenary Session 20 20

View entire presentation